Biomedicine / 背景补读
VAX-31 meets primary trial endpoints, with a comparator exception
Background: Vaxcyte’s October 5 OPUS-1 announcement reports positive primary endpoints for its 31-valent pneumococcal vaccine candidate. These are immune-response results, not demonstrated reductions in infections or regulatory approval.
The randomized, blinded, active-controlled study enrolled 4,047 adults. Responses were assessed after one month. Its prespecified primary rules allowed comparisons with PCV20 and/or PCV21; all 28 shared serotypes passed.
Separately, only 17 of 19 PCV21-shared serotypes passed the stricter threshold: the response-ratio confidence interval’s lower bound had to exceed 0.667. Types 3 and 12F passed only the historical 0.5 threshold. Overall success does not mean every individual comparison succeeded.
These are company topline findings, without a full dataset independently reviewed here. A filing is planned for the first half of 2028.
Sources and further reading
主编加工
Selected through a verified followed account: @FierceBiotech.